MEDI-CAPS LIMITED

CIN: L70100MP1983PLC002231

MCL/SE/2026-2027 **Date: 06.08.2026**

Online filing at: www.listing.bseindia.com

To,
The General Manager
DCS-CRD
BSE Limited
Phiroze Jeejeebhoy Towers, ‘A’ wing
Dalal Street Fort, Mumbai – 400001 (M.H.)

SUBJECT: OUTCOME OF BOARD MEETING HELD ON THURSDAY, 06TH AUGUST, 2026 PURSUANT TO REGULATION 30 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015.

REFERENCE: MEDI-CAPS LIMITED (BSE SCRIP CODE: 523144, ISIN: INE442D01010)

Dear Sir/Madam,

With reference to the above captioned subject and pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform that, Board of Directors at their meeting held on today i.e. Thursday 06th August, 2026 has inter alia considered and approved the following :-

(1) Un-audited Standalone and Consolidated Financial Results of the Company for the quarter ended on 30th June, 2026 along with Limited Review Report thereon. **(Copy of financial results enclosed herewith)**.

(2) Resignation of Mrs. Saloni Garg from the position of Senior Manager and Senior Management Personnel of the Company w.e.f. close of business hours on 06th August, 2026, in view of her appointment as Additional Director as well as Whole Time Woman Director of the Company.

(3) Resignation of Mr. Akshit Garg from the position of General Manager and Senior Management Personnel of the Company w.e.f. close of business hours on 06th August, 2026, in view of his appointment as Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) of the Company.

(4) Based on recommendation of the Audit Committee and the Nomination and Remuneration Committee, approval for appointment of Mrs. Saloni Garg (DIN:11865402) as an “Additional Director as well as Whole Time Woman Director” of the Company for a period of three (3) years w.e.f. 07th August, 2026, to 06th August, 2029 subject to approval of the members of the Company at the ensuing 43rd Annual General Meeting.

(5) Based on recommendation of the Nomination and Remuneration Committee, approval of re-appointment of Mr. Alok K. Garg (DIN: 00274321) Chairman cum Managing Director of the Company for a period of three years w.e.f. 01st September, 2026 to 31st August, 2029 subject to approval of the members of the Company at the ensuing 43rd Annual General Meeting.

(6) Based on recommendation of the Nomination and Remuneration Committee, approval for appointment of Mr. Akshit Garg as a Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) of the company w.e.f. 07.08.2026.

(7) Approval of Board's Report on the operations of the Company along with required annexure and Corporate Governance Report and Management Discussion and Analysis Report for the year ended 31st March, 2026.

(8) Approval for convening of 43rd Annual General Meeting (AGM) on Tuesday, 22nd September, 2026 at 12.30 P.M. (IST) through Video Conferencing (VC) or Other Audio-Visual Means (OAVM).

(9) Other routine businesses with the permission of Chair.

Further, a copy of aforesaid Un-Audited Standalone and Consolidated Financial Results shall also be submitted in XBRL (Integrated Filing Financial) mode within prescribed time limit.

The aforesaid Un-Audited Standalone and Consolidated Financial Results shall also be uploaded on the Company's website www.medicaps.com and on the website of the Stock Exchange at www.bseindia.com. Further, publication containing a Quick Response code and the details of the webpage where complete financial results of the Company are available will be published in Hindi and English Newspapers within prescribed time limit.

Further the requisite Continuous Disclosure's as required pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Schedule III thereof and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-PoD2/I/3762/2026 dated 30th January, 2026 as amended from time to time, are being filed separately with respect to the businesses transacted at the meeting.

The Meeting of the Board of Directors commenced at 03:00 P.M. and concluded at 03.55 P.M.

The above information will also be available on the website of the Company at www.medicaps.com.

This is for your information and record.

Thanking You,

Yours Faithfully,

FOR MEDI-CAPS LIMITED

ALOK K GARG

Digitally signed by ALOK K GARG
Date: 2026.08.06 16:41:11 +05'30'

ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321

Encl.: Un-audited Standalone and Consolidated Financial Results along with limited review report for quarter ended on 30th June, 2026.

RAWKA & ASSOCIATES
CHARTERED ACCOUNTANTS
412, Arcade Silver 56, 1, New Palasia, Indore - 1
☎ Off. : 2541132, Mobile : 9039080380
E-mail : rawkaassociates@gmail.com,. cprawka@gmail.com

LIMITED REVIEW REPORT

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results for the quarter ended 30th June, 2026 of Medi-Caps Limited (the Company) Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

To,
THE BOARD OF DIRECTORS OF
MEDI-CAPS LIMITED
INDORE (M.P.)

SCOPE OF THE REVIEW

1. We have reviewed the accompanying statement of unaudited standalone financial results ("the Statement") of **MEDI-CAPS LIMITED** ("the Company") for the quarter ended 30th June 2026 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended ('SEBI Listing Regulations'), including relevant circulars issued by the SEBI from time to time.

2. The Statement is the responsibility of the Company's Management and has been approved by the Company's Board of Directors. Our responsibility is to issue a report on the Statement based on our review of the Statement, which has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), specified under Section 133 of the Companies Act, 2013 read with relevant rules issued there under, and other accounting principles generally accepted in India and in Compliance with Regulation 33 of the SEBI Listing Regulations.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we

would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

CONCLUSION

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the applicable Indian accounting standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date : 06.08.2026
Place : Indore
UDIN : 26429040SCQNFW8674

For : Rawka & Associates
Chartered Accountants
FRN -021606C

VENUS RAWKA
Digitally signed by VENUS RAWKA
Date: 2026.08.06 16:21:15 +05'30'

Venus Rawka
Partner
Membership No. 429040

MEDI-CAPS LIMITED

REGD. OFFICE: 201, PUSHPRATNA PARADISE, 9/5 NEW PALASIYA, INDORE (M.P.) - 452001 PHONE: 0731-4028148 FAX: 0731-4041435
Website: www.medicaps.com **Email:** investors@medicaps.com **CIN:** L70100MP1983PLC002231

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE 1ST QUARTER ENDED 30.06.2026

(Amount in Lacs except EPS)

S.N.	Particulars	Quarter Ended			Year Ended
		30.06.2026	31.03.2026	30.06.2025	31.03.2026
		Unaudited	Audited	Unaudited	(Audited)
I	**Revenue from Operation**				
	(a) Net sales	4.41	51.37	0.00	228.43
	(b) Other operating income	6.08	1.98	0.00	2.16
	Revenue from Operation	**10.49**	**53.35**	**0.00**	**230.59**
II	**Other Income**	0.37	8.02	31.33	57.65
III	**Total income (I+II)**	**10.86**	**61.37**	**31.33**	**288.24**
IV	**Expenses**				
	a) Cost of material consumed	0.00	0.00	0.00	0.00
	b) Purchase of stock in trade	0.00	0.00	0.00	0.00
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.01	0.08	0.00	0.33
	d) Employee benefits expense	54.38	47.02	45.67	185.32
	e) Finance costs	0.00	0.00	0.00	0.00
	f) Depreciation and amortisation expense	4.65	6.58	4.00	18.58
	g) Power Cost	0.29	0.31	0.58	3.55
	h) Freight Exp.	0.00	0.00	0.00	0.00
	i) Other expenses	10.50	40.11	20.83	92.92
	Total Expenses (IV)	**69.82**	**94.10**	**71.08**	**300.70**
V	**Profit/(Loss) before exceptional item & tax (III-IV)**	**-58.96**	**-32.73**	**-39.75**	**-12.46**
VI	Exceptional items	0.00	0.00	0.00	0.00
VII	**Profit/ (Loss) before tax (V-VI)**	**-58.96**	**-32.73**	**-39.75**	**-12.46**
VIII	Tax expense				
	1) Current Tax	0.00	0.00	0.00	0.00
	2) Earlier year (excess)/Short provision for tax written back	0.00	0.00	0.00	2.85
	3) Deferred Tax	0.00	-1.44	0.00	-1.44
	Total Tax Expenses	**0.00**	**-1.44**	**0.00**	**1.41**
IX	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	**0.00**	**0.00**	**0.00**	**0.00**
X	Profit (Loss) for the period from continuing operations (VII-VIII)	**-58.96**	**-31.29**	**-39.75**	**-13.87**
XI	Profit/(loss) from discontinued operations	0.00	0.00	0.00	0.00
XII	Tax expense of discontinued operations	0.00	0.00	0.00	0.00
XIII	Profit/(loss) from Discontinued operations (after tax) (XI-XII)	**0.00**	**0.00**	**0.00**	**0.00**
XIV	**Share of profit (loss) of associates and joint ventures accounted for using equity method**	**0.00**	**0.00**	**0.00**	**0.00**
XV	Profit/(loss) for the period (X+XIII)	**-58.96**	**-31.29**	**-39.75**	**-13.87**
XVI	Other comprehensive income				
	(a) (i) items that will not be reclassified to statement of profit & loss	101.61	-114.38	54.25	-49.34
	(ii) Income tax on items that will not to be reclassified to statement of P& L	0.00	0.00	0.00	0.00

		Quarter Ended			Year Ended
S.N.	Particulars	30.06.2026	31.03.2026	30.06.2025	31.03.2026
		Unaudited	Audited	Unaudited	(Audited)
	(b) (i) items that will be reclassified to statement of profit & loss	0.00	0.00	0.00	0.00
	(ii) Income tax on items that will be reclassified to statement of P& L	0.00	0.00	0.00	0.00
	Other comprehensive income :	**101.61**	**-114.38**	**54.25**	**-49.34**
XVII	Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	**42.65**	**-145.67**	**14.50**	**-63.21**
XVIII	Profit or Loss Attributable to				
	Profit or Loss Attributable to owners of Parents	0.00	0.00	0.00	0.00
	Profit or Loss Attributable to non-Controlling Interest	0.00	0.00	0.00	0.00
XIX	Total Comprehensive Income for the period Attributable to				
	Total Comprehensive Income for the period Attributable to owners of Parents	0.00	0.00	0.00	0.00
	Total Comprehensive Income for the period Attributable to non-Controlling Interest	0.00	0.00	0.00	0.00
XX	Paid-up equity share capital of the company	1247.00	1247.00	1247.00	1247.00
XXI	Reserve Excluding Revaluation Reserve	0.00	0.00	0.00	5424.19
XXII	Earnings per equity share (for continuing operation)				
	a) Basic (Rs.)	-0.47	-0.25	-0.32	-0.11
	b) Diluted (Rs.)	-0.47	-0.25	-0.32	-0.11
XXIII	Earnings per equity share (for discontinued operation)				
	a) Basic (Rs.)	0.00	0.00	0.00	0.00
	b) Diluted (Rs.)	0.00	0.00	0.00	0.00
XXIV	Earnings per equity share (for discontinued and continuing operation)				
	a) Basic (Rs.)	-0.47	-0.25	-0.32	-0.11
	b) Diluted (Rs.)	-0.47	-0.25	-0.32	-0.11

DATE: 06.08.2026
PLACE: INDORE

For and on behalf of board of directors of
MEDI-CAPS LIMITED

ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321

RAWKA & ASSOCIATES
CHARTERED ACCOUNTANTS
412, Arcade Silver 56, 1, New Palasia, Indore - 1
☎ Off. : 2541132, Mobile : 9039080380
E-mail : rawkaassociates@gmail.com,. cprawka@gmail.com

LIMITED REVIEW REPORT

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results for the quarter ended 30th June, 2026 of Medi-Caps Limited (the Parent Company) Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

To,
THE BOARD OF DIRECTORS OF
MEDI-CAPS LIMITED
INDORE (M.P.)

SCOPE OF THE REVIEW

1. We have reviewed the accompanying Statement of the Consolidated Unaudited Financial Results ("the Statement") of Medi-Caps Limited ("the Parent Company") and its subsidiary (the Parent and its subsidiary together referred to as "the Group"), and its share of the net profit after tax and total comprehensive profit for the quarter ended June 30, 2026, being submitted by the Parent Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the SEBI Listing Regulations'), including relevant circular issued by the SEBI time to time.

2. This Statement, which is the responsibility of the Parent Company's Management and approved by the Parent Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the SEBI Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act,

2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of its wholly-owned subsidiary **Medgel Private Limited**.

CONCLUSION

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the information and explanations given to us by the Parent Company's Management, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of SEBI- (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The consolidated unaudited financial results include the financial results of Medgel Private Limited (wholly owned subsidiary) which also has been reviewed by us and certified by the management, whose interim consolidated financial results reflect a total income of Rs. 283.84 Lakhs, total net loss after tax of Rs. 223.30 Lakhs and total comprehensive income of Rs. 222.04 Lakhs for the quarter ended June 30, 2026 as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the Management, these interim financial statements/ financial information/ financial results are not material to the group.

Our Conclusion on the statement is not modified in respect of the above matter.

Date: 06.08.2026
Place: Indore
UDIN: 26429040GYADVM1271

For, Rawka & Associates
(Chartered Accountants)
FRN 021606C

VENUS RAWKA
Digitally signed by VENUS RAWKA
Date: 2026.08.06 16:22:28 +05'30'

Venus Rawka
(Partner)
M. No.429040

MEDI-CAPS LIMITED

REGD. OFFICE: 201, PUSHPRATNA PARADISE, 9/5 NEW PALASIYA, INDORE (M.P.) - 452001 PHONE: 0731-4028148 FAX: 0731-4041435
Website: www.medicaps.com **Email:** investors@medicaps.com **CIN:** L70100MP1983PLC002231

UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE 1ST QUARTER ENDED 30.06.2026

(Amount in Lacs except EPS)

S.N.	Particulars	Quarter Ended			Year Ended
		30.06.2026	31.03.2026	30.06.2025	31.03.2026
		Unaudited	Audited	Unaudited	(Audited)
I	**Revenue from Operation**				
	(a) Net sales	271.70	342.19	267.65	1239.59
	(b) Other operating income	6.99	2.75	1.11	5.26
	Revenue from Operation	**278.69**	**344.94**	**268.76**	**1244.85**
II	**Other Income**	5.14	558.58	33.49	820.79
III	**Total income (I+II)**	**283.83**	**903.52**	**302.25**	**2065.64**
IV	**Expenses**				
	a) Cost of material consumed	140.16	118.09	169.19	543.87
	b) Purchase of stock in trade	0.00	0.00	0.00	0.00
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-11.57	35.72	-10.35	20.01
	d) Employee benefits expense	191.40	216.95	186.06	774.44
	e) Finance costs	0.00	0.00	1.30	1.30
	f) Depreciation and amortisation expense	45.20	49.78	43.68	180.82
	g) Power Cost	24.42	45.97	53.47	189.08
	h) Freight Exp.	21.62	16.78	39.70	103.01
	i) Other expenses	95.90	117.49	168.39	555.45
	Total Expenses (IV)	**507.12**	**600.78**	**651.44**	**2367.98**
V	**Profit/(Loss) before exceptional item & tax (III-IV)**	**-223.29**	**302.74**	**-349.19**	**-302.34**
VI	Exceptional items	0.00	0.00	0.00	0.00
VII	**Profit/ (Loss) before tax (V-VI)**	**-223.29**	**302.74**	**-349.19**	**-302.34**
VIII	Tax expense				
	1) Current Tax	0.00	0.00	0.00	0.00
	2) Earlier year (excess)/Short provision for tax written back	0.00	0.00	0.00	2.85
	3) Deferred Tax	0.00	-1.44	0.00	-1.44
	Total Tax Expenses	**0.00**	**-1.44**	**0.00**	**1.41**
IX	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	**0.00**	**0.00**	**0.00**	**0.00**
X	Profit (Loss) for the period from continuing operations (VII-VIII)	**-223.29**	**304.18**	**-349.19**	**-303.75**
XI	Profit/(loss) from discontinued operations	0.00	0.00	0.00	0.00
XII	Tax expense of discontinued operations	0.00	0.00	0.00	0.00
XIII	Profit/(loss) from Discontinued operations (after tax) (XI-XII)	**0.00**	**0.00**	**0.00**	**0.00**
XIV	**Share of profit (loss) of associates and joint ventures accounted for using equity method**	**0.00**	**0.00**	**0.00**	**0.00**
XV	Profit/(loss) for the period (X+XIII)	**-223.29**	**304.18**	**-349.19**	**-303.75**
XVI	Other comprehensive income				
	(a) (i) items that will not be reclassified to statement of profit & loss	445.34	-787.70	152.44	-662.74
	(ii) Income tax on items that will not to				

S.N.	Particulars	Quarter Ended			Year Ended
		30.06.2026	31.03.2026	30.06.2025	31.03.2026
		Unaudited	Audited	Unaudited	(Audited)
	be reclassified to statement of P& L	0.00	0.00	0.00	0.00
	(b) (i) items that will be reclassified to				
	statement of profit & loss	0.00	0.00		0.00
	(ii) Income tax on items that will be			0.00	
	reclassified to statement of P& L	0.00	0.00		0.00
	Other comprehensive income :	**445.34**	**-787.70**	**152.44**	**-662.74**
XVII	Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	**222.05**	**-483.52**	**-196.75**	**-966.49**
XVIII	Profit or Loss Attributable to				
	Profit or Loss Attributable to owners of Parents	**-223.29**	**304.18**	**-349.19**	**-303.75**
	Profit or Loss Attributable to non-Controlling Interest	0.00	0.00	0.00	0.00
XIX	Total Comprehensive Income for the period Attributable to				
	Total Comprehensive Income for the period Attributable to owners of Parents	**222.05**	**-483.52**	**-196.75**	**-966.49**
	Total Comprehensive Income for the period Attributable to non-Controlling Interest	0.00	0.00	0.00	0.00
XX	Paid-up equity share capital of the company	1247.00	1247.00	1247.00	1247.00
XXI	Reserve Excluding Revaluation Reserve	0.00	0.00	0.00	9914.18
XXII	Earnings per equity share (for continuing operation)				
	a) Basic (Rs.)	-1.79	2.44	-2.80	-2.44
	b) Diluted (Rs.)	-1.79	2.44	-2.80	-2.44
XXIII	Earnings per equity share (for discontinued operation)				
	a) Basic (Rs.)	0.00	0.00	0.00	0.00
	b) Diluted (Rs.)	0.00	0.00	0.00	0.00
XXIV	Earnings per equity share (for discontinued and continuing operation)				
	a) Basic (Rs.)	-1.79	2.44	-2.80	-2.44
	b) Diluted (Rs.)	-1.79	2.44	-2.80	-2.44

DATE: 06.08.2026
PLACE: INDORE

For and on behalf of board of directors of
MEDI-CAPS LIMITED

ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321

MEDI-CAPS LIMITED

REGD. OFFICE: 201, PUSHPRATNA PARADISE, 9/5 NEW PALASIYA, INDORE (M.P.) - 452001 PHONE: 0731-4028148 FAX: 0731-4041435
Website: www.medicaps.com **Email:** investors@medicaps.com **CIN:** L70100MP1983PLC002231

UNAUDITED CONSOLIDATED SEGMENTWISE REVENUE, RESULTS AND CAPITAL EMPLOYED FOR THE 1ST QUARTER ENDED 30.06.2026

(Amount in Lacs)

S.No.	Segment Revenue	Quarter Ended			Year Ended
		30.06.2026	31.03.2026	30.06.2025	31.03.2026
		Unaudited	Audited	Unaudited	Audited
1	**Segment Revenue**				
	Pharma Division	268.20	291.59	268.76	1014.26
	Real Estate Division	10.49	53.35	0.00	230.59
	Other	0.00	0.00	0.00	0.00
	Net Sale/Income From Operations	**278.69**	**344.94**	**268.76**	**1244.85**
2	**Segment Results (Profit) (+)/ Loss (-) before tax and Interest**				
	Pharma Division	-164.33	335.47	-308.14	-288.58
	Real Estate Division	-58.96	-32.73	-39.75	-12.46
	Other	0.00	0.00	0.00	0.00
	Total	**-223.29**	**302.74**	**-347.89**	**-301.04**
	Interest Income	0.00	0.00	0.00	0.00
	Interest Expenses	0.00	0.00	1.30	1.30
	Other Unallocable Expenditure net off	0.00	0.00	0.00	0.00
	Unallocable Income	0.00	0.00	0.00	0.00
	Profit Before Tax	**-223.29**	**302.74**	**-349.19**	**-302.34**
3	**Capital Employed**				
	Segment Assets (A)				
	Pharma Division	4560.63	4812.41	5491.74	4812.41
	Real Estate Division	6667.00	6734.01	6810.76	6734.01
	Other	0.00	0.00	0.00	0.00
	Total (A)	**11227.63**	**11546.42**	**12302.50**	**11546.42**
	Segment Liabilities (B)				
	Pharma Division	234.98	322.43	309.72	322.43
	Real Estate Division	55.50	62.82	61.86	62.82
	Other	0.00	0.00	0.00	0.00
	Total (B)	**290.48**	**385.25**	**371.58**	**385.25**
4	**Total Capital Employed (Segment Assets-Segment Liabilities)**				
	Pharma Division	4325.65	4489.99	5182.02	4489.99
	Real Estate Division	6611.50	6671.19	6748.90	6671.19
	Other	0.00	0.00	0.00	0.00
	Total Capital Employed (Segment Assets-Segment Liabilities)	**10937.15**	**11161.18**	**11930.92**	**11161.18**

DATE: 06.08.2026
PLACE: INDORE

For and on behalf of board of directors of
MEDI-CAPS LIMITED

ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321

NOTES:

1. The above standalone and consolidated unaudited financial results for the Quarter ended June 30, 2026 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in its meeting held on August 06, 2026. The above results have been reviewed by Statutory Auditors of the Company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Company's Management has exercised the necessary due diligence to ensure that the financial results provide a true and fair view of its affairs.

2. This above standalone and consolidated unaudited financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.

3. The above consolidated results included the results of the wholly owned subsidiary company i.e. Medgel Private Limited.

4. The Company has two reportable segments for the Consolidated Financial Statements which consists of the Pharma division and Real Estate division in accordance with Ind AS-108 Operating Segment and the same is enclosed with this result.

5. During this quarter the Company generated revenue of Rs. 4.41 Lacs from sale of shops at Medi-caps Business Park.

6. The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or re-casted wherever found necessary.

7. The aforesaid unaudited financial Results will be uploaded on the Company's website **www.medicaps.com** and will also be available on the websites of the Stock exchange i.e. **www.bseindia.com** for the benefit of shareholders and investors. Further, publication containing a Quick Response code and the details of the webpage where complete financial results of the Company are available, will be published in English and Hindi Newspapers within prescribed time limit.

8. The figures of the quarter ended March 31, 2026 are the balancing figure between the audited figures in respect of the full financial year and the year to date figures up to the first quarter which were subject to limited review.

DATE: 06.08.2026
PLACE: INDORE

For and on behalf of the Board of Directors of
MEDI-CAPS LIMITED

ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321